Pipeline

July 22, 2019

Company	Drug/Device	Medical Condition	Status
Compass Therapeutics	CTX-471	metastatic or locally advanced solid cancers	Phase 1 trial initiated
Cyxone	T20K	multiple sclerosis (MS)	Phase 1 trial initiated
SOTIO	SO-C101	advanced/metastatic solid tumors	Phase 1/1b trial initiated
TARIS Bio	TAR-200 in combination with Opdivo (nivolumab)	muscle-invasive bladder cancer (MIBC)	Phase 1b trial initiated enrolling 25 subjects with MIBC who are scheduled for radical cystectomy
Metacrine, Inc.	MET409	non-alcoholic steatohepatitis (NASH)	Phase 1b trial initiated
IDEAYA Biosciences, Inc.o	IDE196	solid tumors that harbor GNAQ/11 mutations or PRKC fusions	Phase 1/2 trial initiated
Trovagene, Inc.	onvansertib in combination with FOLFIRI and Avastin (bevacizumab)	metastatic colorectal cancer (mCRC) with a KRAS mutation (NCT03829410)	Phase 1b/2 trial initiated
EIP Pharma, Inc.	neflamapimod	Huntington's disease	Phase 2 trial initiated enrolling 16 subjects at a site in Cambridge UK
Cara Therapeutics, Inc.	Oral KORSUVA (CR845/difelikefalin)	pruritus in subjects with atopic dermatitis (AD)	Phase 2 trial initiated enrolling 240 adult subjects with AD
Dilafor AB	tafoxiparin	pregnant women planned for labor induction	Phase 2b trial initiated
NeuroRx, Inc.	NRX-101	Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB)	Phase 2b/3 trial initiated enrolling 140 subjects with Severe Bipolar Depression and ASIB who are stabilized following a single IV infusion of ketamine JPS Health Network in Fort Worth, Texas
Mirum Pharmaceuticals	maralixibat	progressive familial intrahepatic cholestasis (PFIC) in pediatric subjects	Phase 3 trial initiated enrolling 30 subjects with residual BSEP function (PFIC2 non-truncating) aged one to 17 years
CStone Pharmaceuticals	avapritinib	gastrointestinal stromal tumors (GIST)	Phase 3 trial initiated
Sensorion	SENS-401	Sudden Sensorineural Hearing Loss (or SSNHL)	IND approval granted by the FDA
Karyopharm Therapeutics	selinexor in combination with dexamethasone	relapsed refractory multiple myeloma in subjects who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody	Approval granted by the FDA
ConTIPI Medical, Ltd.	ProVate	pelvic prolapse in women	Approval granted by the FDA
Azurity Pharmaceuticals	Katerzia (amlodipine) Oral Suspension, 1 mg/mL	hypertension (high blood pressure) in adults and pediatric patients six years of age and older and coronary artery disease in adults	Approval granted by the FDA